| Bioactivity | Romifidine is an α2 adrenergic receptor agonist. Romifidine shows sedation effects in vivo[1][2]. | ||||||||||||
| In Vivo | Romifidine (80 μg/kg; i.v. once) produces sedative effects with significantly greater drooping during the 45-90 min time period in welsh mountain ponies[1].Romifidine (40, 80 and 120 mg/kg; i.v. at seven-day intervals) shows a shallower and shorter-lived sedation than with detomidine in horses[2]. | ||||||||||||
| Name | Romifidine | ||||||||||||
| CAS | 65896-16-4 | ||||||||||||
| Formula | C9H9BrFN3 | ||||||||||||
| Molar Mass | 258.09 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. England GC, et al. A comparison of the sedative effects of three alpha 2-adrenoceptor agonists (romifidine, detomidine and xylazine) in the horse. J Vet Pharmacol Ther. 1992 Jun;15(2):194-201. [2]. Hamm D, et al. Sedative and analgesic effects of detomidine and romifidine in horses. Vet Rec. 1995 Apr 1;136(13):324-7. |